Acceptability of pre-exposure prophylaxis as an HIV prevention strategy: Barriers and facilitators to pre-exposure prophylaxis uptake among at-risk peruvian populations

International Journal of STD and AIDS

Volumn 22, Issue 5, 2011, Pages 256-262

  Galea, J T ^a   Kinsler, J J ^b   Salazar, X ^a,c   Lee, S J ^d   Giron, M ^e   Sayles, J N ^b   Caceres C ^b   Cunningham, W E ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSIDAD PERUANA CAYETANO HEREDIA   (Peru)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Acceptability; FSW; HIV; MSM; Pre exposure prophylaxis (PrEP); South America

Indexed keywords

ANTIVIRUS AGENT;

ADULT; ARTICLE; AWARENESS; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DIZZINESS; DRUG EFFICACY; FEMALE; HEALTH CARE PERSONNEL; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MALE HOMOSEXUAL; NAUSEA; PERU; POPULATION RESEARCH; PRIORITY JOURNAL; PROPHYLAXIS; PROSTITUTION; RISK ASSESSMENT; SOCIAL ASPECT; TRANSSEXUALISM;

ADULT; CHEMOPREVENTION; FEMALE; FOCUS GROUPS; HIV INFECTIONS; HOMOSEXUALITY, MALE; HUMANS; MALE; PATIENT ACCEPTANCE OF HEALTH CARE; PERU; PROSTITUTION; TRANSVESTISM;

EID: 79957678752     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/ijsa.2009.009255     Document Type: Article

References (40)

1. Steinbrook R. One step forward, two steps back-will there ever be an AIDS vaccine? N Engl J Med 2007;357:2653-2655
2. Vissers DC, Voeten HA, Nagelkerke NJ, et al. The impact of pre-exposure prophylaxis (PrEP) on HIV epidemics in Africa and India: a simulation study. PLoS One 2008;3:e2077
3. Skoler-Karpoff S, Ramjee G, Ahmed K, et al. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet 2008;372:1977-1987
4. Youle M, Wainberg MA. Pre-exposure chemoprophylaxis (PREP) as an HIV prevention strategy. J Int Assoc Physicians AIDS Care (Chic Ill) 2003;2:102-105
5. Smith SM. Pre-exposure chemoprophylaxis for HIV: it is time. Retrovirology 2004;1:16
6. Stephenson J. New HIV prevention strategies urged: averting new infections key to controlling pandemic. JAMA 2004;292:1163-164
7. Cohen MS, Gay C, Kashuba AD, et al. Narrative review: antiretroviral therapy to prevent the sexual transmission of HIV-1. Ann Intern Med 2007;146:591-601
8. Liu AY, Kittredge PV, Vittinghoff E, et al. Limited knowledge and use of HIV post- and pre-exposure prophylaxis among gay and bisexual men. J Acquir Immune Defic Syndr 2008;47:241-247
9. Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 1999;354:795-802
10. Lallemant M, Jourdain G, Le Coeur S, et al. Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. N Engl J Med 2004;351:217-228
11. PrEP-Watch. Ongoing and Planned PrEP Trials as of December 2008. See http://www.PrEPwatch.org/pdf/Trials/PrEP_trials_table.pdf (last checked 2 March 2009)
12. Goicohea P, Lama JR, Leon R, Grant RM. Reducing participant's information gap in HIV prevention clinical research. AIDS 2008 - XVII International AIDS Conference, 2008
13. Lama JR, Guanira J, Goicochea P, et al. Willingness to participate in a HIV pre-exposure prophylaxis efficacy trial among high risk men who have sex with men in the Andean region. 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention, 2007
14. Nodin N, Carballo-Dieguez A, Ventuneac AM, et al. Knowledge and acceptability of alternative HIV prevention bio-medical products among MSM who bareback. AIDS Care 2008;20:106-115
15. Kellerman SE, Hutchinson AB, Begley EB, et al. Knowledge and use of HIV pre-exposure prophylaxis among attendees of minority gay pride events, 2004. J Acquir Immune Defic Syndr 2006;43:376-377
16. UNAIDS. Report on the global AIDS epidemic. Geneva, Switzerland: UNIAIDS, 2008
17. Montano SM, Sanchez JL, Laguna-Torres A, et al. Prevalences, genotypes, and risk factors for HIV transmission in South America. J Acquir Immune Defic Syndr 2005;40:57-64
18. Miller GA, Mendoza W, Krone MR, et al. Clients of female sex workers in Lima, Peru: a bridge population for sexually transmitted disease/HIV transmission? Sex Transm Dis 2004;31:337-342
19. Sayles JN, Macphail C, Newman P, Cunningham WE. Future HIV vaccine acceptability among young adults in South Africa. J Health Educ Behav 2010;37:193-210
20. Sandelowski M. The problem of rigor in qualitative research. Adv Nurs Sci 1986;8:27-37
21. Muhr T. User's Manual for ATLAS.ti 5.0. Berlin: ATLAS.ti Scientific Software Development, 2004
22. Green PE, Srinivasan V. Conjoint analysis in consumer research: issues and outlook. J Consumer Res 1978;5:103-123
23. Green PE, Srinivasan V. Conjoint analysis in marketing: new developments with implications for research and practice. J Marketing 1990;54:3-19
24. Luce RD, Tukey JW. Simultaneous conjoint measurement: a new type of fundamental measurement. J Math Psychol 1964;1:1-27
25. Hay J. Conjoint analysis in pharmaceutical research. J Manag Care Pharm 2002;8:206-208
26. Phillips KA, Maddala T, Johnson FR. Measuring preferences for health care interventions using conjoint analysis: an application to HIV testing. Health Serv Res 2002;37:1681-1705
27. Ryan M, Farrar S. Using conjoint analysis to elicit preferences for health care. BMJ 2000;320:1530-1533
28. Newman PA, Duan N, Lee SJ, et al. HIV vaccine acceptability among communities at risk: the impact of vaccine characteristics. Vaccine 2006;24:2094-2101
29. Lee SJ, Brooks RA, Newman PA, et al. HIV vaccine acceptability among immigrant Thai residents in Los Angeles: a mixed-method approach. AIDS Care 2008;20:1161-1168
30. Newman PA, Duan N, Lee SJ, et al. Willingness to participate in HIV vaccine trials: the impact of trial attributes. Prev Med 2007;44:554-557
31. Duan N. Listening to consumers and HIV vaccine PrEParedness. Lancet 2005;365:1119-1121
32. Ryan M, McIntosh E, Shackley P. Methodological issues in the application of conjoint analysis in health care. Health Econ 1988;7:373-378
33. Valencia-Garcia D, Starks H, Strick L, et al. After the fall from grace: negotiation of new identities among HIV-positive women in Peru. Cult Health Sex 2008;10:739-752
34. Clark JL, Long CM, Giron JM, et al. Partner notification for sexually transmitted diseases in Peru: knowledge, attitudes, and practices in a high risk community. Sex Transm Dis 2007;34:309-313
35. Abbas UL, Anderson RM, Mellors JW. Potential impact of antiretroviral chemoprophylaxis on HIV-1 transmission in resource-limited settings. PLoS ONE 2007;2:e875
36. Guest G, Johnson L, Burke H, et al. Changes in sexual behavior during a safety and feasibility trial of a microbicide/diaphragm combination: an integrated qualitative and quantitative analysis. AIDS Educ Prev 2007;19:310-320
37. Cassell M, Halperin D, Shelton J, et al. Risk compensation: the Achilles' heel of innovations in HIV prevention. BMJ 2006;332:605-607
38. Pinkerton S. Sexual risk compensation and HIV/STD transmission: empirical evidence and theoretical considerations. Risk Anal 2001;21:727-36
39. Newman PA, Duan N, Rudy ET, Roberts KJ, Swendeman D. Posttrial HIV vaccine adoption: concerns, motivators, and intentions among persons at risk for HIV. J Acquir Immune Defic Syndr 2004;37:1393-1403
40. Liau A, Zimet GD. The acceptability of HIV immunization: examining vaccine characteristics as determining factors. AIDS Care 2001;13:643-650